Recent evidence also suggests that HDAC inhibitors may affect cancer cell metabolism, namely: HT29 colorectal cancer cells treated with the HDAC inhibitors, butyrate, or trichostatin showed a reduction in lactate production and glucose uptake. Here, HDAC9 is linked to cancer.